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Small amounts of cell-free DNA circulate in both healthy and diseased human blood, while increased
concentrations of DNA are present in the serum of cancer patients. Tumor-specific mutations or epigenetic
modifications have predominantly been detected in tissue specimens. The purpose of this study was to
investigate methylation of five different genes involved in tumor suppression and DNA repair (suppressors of
cytokine signaling 1 and 2 (SOCS1, SOCS2)), Ras-association domain family protein 1A (RASSF1a), D-type
p16INK4a cyclin-dependent kinase inhibitor (CDKN), and O6-methylguanine DNA-methyltransferase (MGMT)) in
the serum of 100 patients using methylation-specific PCR. In all, 41 melanoma patients (stage I¼ 18; stage II¼ 10;
stage III/IV¼ 13), 13 healthy controls without nevi, and 10 individuals with more than 15 nevi of 45 mm in size
were investigated. For comparison, sera from patients with other skin tumors (nine basal cell cancers, five
Kaposi’s sarcoma), different metastasized cancers (five breast cancers, five colon cancers), and several chronic
inflammatory diseases (n¼ 12) were also analyzed. In addition, we examined if methylation was involved in
silencing transcription of these genes in 12 melanoma specimens. SOCS1, SOCS2, RASSF1a, CDKN2a, and
MGMT were methylated in 75, 43, 64, 75, and 64% of melanoma samples, respectively. Of the 41 melanoma
patients, 83% had one hypermethylated gene, while 66, 51, and 41% had two, three, or four hypermethylated
genes, respectively. Also, 20% of these patients showed hypermethylation for all genes, while only 17% showed
no methylation. Importantly, the methylation profile of the selected genes from melanoma patients was distinct
from the other analyzed tumors. Transcription of SOCS1, SOCS2, CDKN2a, and RASSF1a genes was significantly
reduced in fresh melanoma samples, while MGMT showed a 12-fold upregulation at the messenger ribonucleic
acid level (Po0.001). Our findings suggest that epigenetic silencing of the studied tumor suppressor genes is a
common and probably important mechanism for melanoma formation. This convenient method using a simple
blood sample may contribute to classification of melanoma and awaits clinical validation.
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INTRODUCTION
The presence of circulating nucleic acids in serum and
plasma has been described many years ago (Mandel and
Me´tais, 1947; Tan et al., 1966; Koffler et al., 1973). By using
radioimmunoassays, it has been discovered that cancer
patients have higher levels of circulating DNA than those
with nonmalignant diseases and healthy controls (Leon et al.,
1977). With the development of more sensitive molecular
techniques such as semiquantitative PCR, a renewed interest
in circulating DNA has emerged. Many studies have
focused on the detection of genetic changes in DNA isolated
from tumor tissue. A major effort has been placed on the
detection of mutations, loss of heterozygosity, microsatellites,
and the methylation status of such DNA (Vasioukhin et al.,
1994; Nawroz et al., 1996; Wong et al., 1999). A
considerable proportion of the circulating DNA is released
during apoptotic cell death. The rate of apoptosis is
dysregulated in many pathological conditions such as
degenerative, traumatic, ischemic, inflammatory, and malig-
nant diseases (Holdenrieder et al., 2005). Several studies
have demonstrated tumor-specific alterations in DNA recov-
ered from plasma or serum of patients with various
malignancies, a finding with great potential for molecular
diagnosis and prognosis estimation (Fujiwara et al., 1999;
Johnson and Lo, 2002; Sidransky, 2002; Usadel et al., 2002).
Recently, Widschwendter and Jones (2002) have described
the potential of circulating DNA in the serum of women
with breast cancer to predict the course of disease by
analyzing DNA methylation of tumor suppressor genes
(TSGs). Very recently, the potential of circulating DNA as a
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prognostic tool for squamous cell carcinoma (Hamana et al.,
2005) and gastric cancer (Leung et al., 2005) has been
reported.
In higher eukaryotes, DNA is methylated exclusively at
cytosines located 50 to guanosine within cytosine-phospho-
guanosine (CpG) dinucleotides. This modification has im-
portant regulatory effects on gene expression, especially
when involving CpG-rich areas known as CpG islands,
located in or near the promoter regions of many genes (Jones
and Baylin, 2002; Laird, 2003). While almost all gene-
associated islands are protected from methylation on auto-
somal chromosomes, extensive methylation of CpG islands
has been associated with transcriptional inactivation of
selected imprinted genes and genes on the inactive
X-chromosome of females (Singer-Sam et al., 1990). Aberrant
methylation of normally unmethylated CpG islands has been
documented as a relatively frequent event in immortalized
and transformed cells, and has been associated with
transcriptional inactivation of defined TSG in human cancer
(Dammann et al., 2000). Notably, this alteration has been
described to occur in a very early stage of carcinogenesis
(Fujiwara et al., 2005).
Our study evaluated the methylation status of five
different TSGs/DNA repair genes (suppressors of cytokine
signaling (SOCS)1, SOCS2, Ras-association domain family
protein 1A (RASSF1a), cyclin-dependent kinase inhibitor
(CDKN)2a, and O6-methylguanine DNA-methyltransferase
(MGMT)) in the serum of 41 melanoma patients. Moreover,
the messenger ribonucleic acid transcripts for these genes
were also studied in melanoma lesions relative to normal
skin. We provide evidence for epigenetic inactivation and
reduced TSG expression in the serum and tissue of melanoma
patients.
RESULTS
Patients
Patients’ characteristics are depicted in Table 1A and B.
Patients suffered from primary melanoma (n¼28; mean age:
60.3 years, range 36–78 years) and metastases (n¼13; mean
age: 61.8 years, range 23–78 years). In all, 13 healthy
individuals without nevi 45 mm (mean age: 54 years, range
37–71 years) and 10 patients with more than 15 benign nevi
45 mm (mean age: 39 years, range 21–65 years) were used as
controls (Table 1C). For comparison, sera from patients with
other skin tumors (nine basal cell cancers, five Kaposi’s
sarcoma) as well as different metastasized cancers (five breast
cancers, five colon cancers) and 12 patients with chronic
inflammatory diseases (psoriasis and eczema) were also
analyzed (Table 1C).
Detection of cell-free DNA in plasma
The average DNA recovered from donor controls was 26.5 ng
DNA/ml, and from melanoma patients 56 ng DNA/ml,
respectively (Figure 1). Likewise, patients with other meta-
static cancers also had elevated levels (Figure 1). Patients
with nonmetastasizing basal cell cancers had the lowest
concentrations of cell-free DNA (Po0.05 compared to
healthy controls) despite their high mean age of 77 years
(Figure 1). Individuals suffering from chronic inflammatory
diseases also showed moderately elevated levels of circulat-
ing DNA compared with healthy individuals of different age
(Figure 1).
Quantitative methylation analysis of selected genes
Initially, five candidate genes involved in tumor suppression,
cell cycle, and DNA repair (SOCS1, SOCS2, RASSF1a,
CDKN2a (p16INK2a), and MGMT) were selected for analysis
of CpG promoter regions using methylation-specific PCR. The
results indicated that the most frequently methylated genes in
the serum were SOCS1 (75%), CDKN2a (75%), RASSF1a
(64%), MGMT (64%), and SOCS2 (43%), respectively
(Table 2). In more detail, a box plot analysis provides an
excellent visual summary of the quantitative distribution of
methylated promoter DNA (Figure 2). The box stretches from
the lower hinge (defined as the 25th percentile) to the upper
hinge (the 75th percentile) and therefore contains the middle
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Figure 1. Levels of circulating DNA (ng/ll) recovered from different patient groups and healthy controls.
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Table 1. Clinical characteristics of patients with primary melanoma (A), metastatic melanoma (B) and controls
(C) used for serum DNA methylation studies
(A) Primary melanoma patients
No.
Age
(years) Gender Diagnosis
Clark
level
Breslow
(mm)
Year of first
diagnosis
(month/year) Localization of tumor
1 60 W Primary melanoma II 0.55 08/04 Right lower leg
2 36 M Primary melanoma III 1.37 06/04 Forearm right
3 41 W Primary melanoma III 0.59 09/04 Back of the left hand
4 43 W Primary melanoma IV 0.6 06/99 Upper back
5 77 W Primary melanoma II 0.74 08/01 Plantar left
6 41 W Primary melanoma III 0.63 04/02 Lower back
7 70 M Primary melanoma III 0.89 09/04 Back
8 61 M Primary melanoma IV 0.8 09/04 Upper arm
9 64 W Primary melanoma III 0.3 09/04 Lower leg left
10 53 M Primary melanoma III 0.66 11/01 Back
11 62 M Primary melanoma III 0.45 01/00 Lower leg
12 62 W Primary melanoma III–IV 0.88 05/00 Left shoulder
13 65 W Primary melanoma III 0.82 09/04 Back
14 71 M Primary melanoma IV 4.2 09/04 Back of the left hand
15 76 M Primary melanoma IV 2.3 08/04 Back
16 78 W Primary melanoma IV 3.24 05/03 Lower right leg
17 65 M Primary melanoma IV 2.15 04/04 Back
18 73 M Primary melanoma IV 0.55 06/04 Abdomen right
19 37 M Primary melanoma III 2.2 02/96 Left thigh
20 66 W Primary melanoma III–IV 0.5 05/04 Scalp
21 69 M Primary melanoma IV 2.0 06/04 Lower back
22 67 W Primary melanoma IV 4.23 03/05 Back
23 62 M Primary melanoma IV 1.6 05/05 Lower right leg
24 40 W Primary melanoma IV 4.0 06/05 Scalp
25 70 M Primary melanoma III–IV 0.82 07/05 Left arm
26 72 M Primary melanoma II–III 0.9 08/05 Scalp
27 40 M Primary melanoma II 0.5 08/05 Back
28 66 W Primary melanoma II 0.45 08/05 Lower leg
(B) Metastatic melanoma patients
No. Age
(years)
Gender Diagnosis Localization of metastases
29 78 W Metastatic melanoma Lymph node and breast
30 51 W Metastatic melanoma Lymph node
31 68 W Metastatic melanoma Lymph node, intestine, and
cerebral
32 67 W Metastatic melanoma Bone
33 54 W Metastatic melanoma Cerebral and lungs
34 46 W Metastatic melanoma Cutaneous and lungs
35 72 M Metastatic melanoma Lymph node and lungs
36 23 M Metastatic melanoma Cerebral
Table 1 continued on following page
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half of the scores in the distribution. The median is shown as
a line across the box. As can be seen in Figure 2, primary
melanoma and melanoma metastases generally demonstrated
the highest levels of methylation (Figure 2).
Of the 41 melanoma patients, 83% had one hypermethy-
lated gene, while 66, 51, and 41% had two, three, or four
hypermethylated genes, respectively. In all, 20% of these
patients showed hypermethylation for all genes and only 17%
showed no methylation. In basal cell cancers 86% had
methylated RASSF1a and 43% had methylated CDKN2a
(p16INK2a), while the other genes showed methylations in less
than 30% (Table 2 and Figure 2). Serum from patients with
other metastasized cancers showed methylation of individual
genes in up to 20% (Table 2). Serum from 10 nevus
patients as well as from healthy controls without nevi showed
no significant methylation (Table 2 and Figure 2). Impor-
tantly, the methylation profile of the selected genes from
melanoma patients was distinct from the other tumors
analyzed. Interestingly, individuals suffering from chronic
inflammatory diseases showed a high level (75%) of
methylation for CDKN2A (Table 2). The methylation analysis
for the different age groups showed no significant differences
either for patients or for healthy controls (Table 2 and data not
shown).
Gene expression of target genes in primary tumors
The mRNA expression of SOCS1, SOCS2, CDKN2a (p16INK2a),
RASSF1a, MGMT and b-actin was assessed by real-
time PCR in 12 melanoma patients and normalized to three
different normal human melanocyte cultures. Transcripts
37 64 W Metastatic melanoma Lymph node and breast
38 70 M Metastatic melanoma Liver and lungs
39 65 W Metastatic melanoma Lymph node and cutaneous
40 68 W Metastatic melanoma Cutaneous
41 77 W Metastatic melanoma Cutaneous
(C) Controls for serum DNA methylation studies
Specimens
Basal cell
carcinoma
Kaposi’s
sarcoma
Breast
cancer
Colon
cancer
Healthy
controls
Chronic inflam.
diseases Nevus Total
No. of patients 9 5 5 5 13 12 10 59
9445 0o45
4o45 12445
Gender
Female 8 0 4 2 7445 0o45 5 32
2o45 4445
Male 1 5 1 3 2445 0o45 5 27
2o45 8445
Mean age (years) 77 54 45 72 54 65 39 58
Table 1. continued
No. Age (years) Gender Diagnosis Localization of metastases
Table 2. Frequency of promoter methylation for the different analyzed genes in the melanoma group and different
control groups
SOCS1 (%) SOCS2 (%) RASSF1A (%) CDKN2A (%) MGMT (%)
Metastatic melanoma 31 23 62 54 15
Primary melanoma 75 43 64 75 64
Basal cell carcinoma 14 29 86 43 29
Kaposi’s sarcoma 20 20 40 40 0
Other metastatic cancers 20 0 10 10 0
Nevi 20 20 10 30 0
Chronic inflam. diseases 17 33 8 75 8
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were significantly downregulated for: SOCS1 (0.57; Po0.05),
SOCS2 (0.13; Po0.005), CDKN2a (p16INK2a) (0.1; Po0.001),
and RASSF1a (0.3; Po0.005) (Table 3). Interestingly, MGMT
showed a significant upregulation (12.4 times, Po0.001)
in comparison with normal human melanocyte cultures
(Table 3).
Pyrosequencing of SOCS2
To further analyze the positional methylation of the pro-
moter region, we selected the SOCS2 gene that showed
strongly reduced transcript levels in melanoma specimens
and significant qualitative methylation. Two different
CpG sites (#1 at position 2,249 and #2 at 2,258) were
analyzed (Figures 3 and 4a). As compared to the SOCS2
threshold of 0.2 in healthy individuals, all methylation events
at position #2 from the DNA of patients with primary
melanoma and metastases were considered significant
(Figure 4b).
DISCUSSION
Cancer is one of the most common reasons for death in the
world. Early detection and close follow-up are crucial for
Table 3. Gene expression levels of the target genes in melanoma patients (n=12) analyzed by real-time PCR of
melanoma specimens
SOCS1 SOCS2 RASSF1a CDKN2a MGMT
Average expression level 0.5770.87 0.1372.73 0.3070.90 0.1071.03 12.4270.81
t-test Po0.05 Po0.005 Po0.005 Po0.001 Po0.001
The gene expression level of the studied TSG was normalized to three pooled NHM cultures. As depicted, the expressions of SOCS1, SOCS2, RASSF1a, and
CDKN2a were significantly downregulated, while MGMT showed a significantly higher level.
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Figure 2. Quantitative methylation of the analyzed genes in different patient groups. The median, the lower and upper quartiles (depicted as a box), and
maximum and minimum, being represented by the length of the vertical line, are shown. Numbers were calculated as described in Materials and Methods, and
depicted on a log scale.
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successful management. Definitive diagnosis requires a tumor
biopsy, but an easy and reliable noninvasive test for detecting
and monitoring disease progression would have many
advantages. No such test is currently available. One attractive
approach for cancer detection is to detect tumor-specific DNA
alterations in DNA extracted from patients’ blood. It is known
that DNA fragments frequently appear in measurable quan-
tities in the serum or plasma of cancer patients.
Aberrant hypermethylation of CpG islands in promoter
regions has been shown to be associated with transcriptional
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silencing of various genes in several types of cancer (Nagai
et al., 2002, 2003; Fukushima et al., 2003; Galm et al., 2003;
He et al., 2003; Uehara et al., 2003; Yang et al., 2003;
Li et al., 2004). Profiling studies have revealed the frequency
of gene hypermethylation and identified specific genes
for different histological origins (Esteller et al., 2001;
Widschwendter and Jones, 2002; Toyooka et al., 2003).
However, there are only very few studies which have focused
on gene hypermethylation in primary tumors versus meta-
stases (Hoon et al., 2004). There is a clear indication that
hypermethylation of the TSG promoter region is an essential
mechanism by which gene transcription may be turned off in
cancer cells.
Of the five genes studied, we found that the most
frequently methylated genes in the serum of melanoma
patients were SOCS1 and CDKN2a (p16INK2a), followed by
RASSF1a, MGMT, and SOCS2. The analysis for methylation
in the different stage and age groups revealed no significant
differences.
For instance, the SOCS proteins have an important role as
attenuators of cytokine-mediated processes, suggesting a role
in the suppression of tumorigenesis. Recently, SOCS-1 was
found to be frequently silenced by hypermethylation in
hepatocellular carcinoma (Yoshikawa et al., 2001), SOCS-1,
and SOCS-3 in squamous cell carcinoma of the head
and neck (Weber et al., 2005), pancreatic carcinoma
(Fukushima et al., 2003), and hepatoblastomas (Yang et al.,
2003), and as newly reported by Sutherland et al. (2004)
SOCS1 is also involved in breast cancer and primary ovarian
cancer, while SOCS-2 is hypermethylated only in primary
ovarian cancer.
Until today there are no studies looking at the expression
and methylation of SOCS1 and SOCS2 in cutaneous
melanoma in serum. Recently, Li et al. (2004) have shown
the presence of SOCS1 in eight melanoma cell lines
derived from different tumor stages and primary melanoma,
respectively. Our data extend their finding showing
significant methylation of SOCS1 in the sera of melanoma
patients, leading to reduced SOCS1 gene transcription
in vivo.
Understanding the physiological role of RASSF1a is still in
its early stage (Agathanggelou et al., 2005). As reported by
Dammann et al. (2000), hypermethylation of the RASSF1a
gene promoter correlates with loss of gene expression in lung
cancer. Further studies have shown that the aberrant
methylation of this gene is involved in many types of
carcinomas, including breast, prostate, ovarian, kidney,
gastric bladder, and nasopharyngeal (Lo et al., 2001; Liu
et al., 2002). As shown by Spugnardi et al. (2003), RASSF1a is
inactivated due to hypermethylation of its CpG islands in
melanoma cell lines and tumor biopsies. Since we also
observed a significant downregulation of RASSF1a in
melanoma tissue, we decided to look at the methylation of
the promoter region of this gene in the sera of melanoma
patients. Our data on RASSF1a methylation in serum
confirmed the finding of Spugnardi et al. (2003) obtained
from tumor tissue and cell lines.
The p16INK4a gene encodes a protein, P16, which is a
D-type cyclin-dependent kinase inhibitor that blocks the
ability of CDK4 to interact with cyclin D and stimulate the
progression of eukaryotic cells through the G1 phase of the
cell cycle (Serrano et al., 1993). To date, CDKN2a (p16INK2a)
has been the most studied gene for aberrant promoter
methylation in melanoma (Fujimoto et al., 1999; Merbs and
Sidransky, 1999). By studying the methylation status of this
gene in patient serum, we have shown that there is a high
frequency of methylation in melanoma and basal cell cancer
patients. This result correlates well with decreased mRNA
Table 4. Hybridization probes and primers were designed using Primer Expresss version 2.0 (Perkin-Elmer
Applied Biosystems Inc., Warrington, UK), based on sequences from the GenBank database (top: primer
sequences used for real-time PCR with SYBRs assay; bottom: primer sequences used for MSP)
Gene Gene location Forward primer Reverse primer
b-Actin 50-AAG TAG GCG CAC AGT AGG TCT GA 50-GTG CAA AGA ACA CGG CTA AGT G
SOCS-1 16p13.3 50-CCG TGC ACG CAG CAT TAA C 50-GGC GCC TCG CCC CTA
SOCS-2 12q12 50-GGA TGG TAC TGG GGA AGT ATG ACT 50-AGT CGA TCA GAT GAA CCA CAC TCT C
RASSF1a 3p21 50-ACC TCT GTG GCG ACT TCA TCT 50-AGG TGA ACT TGC AAT GCG
MGMT 10q26 50-ACC AGG TTC CCC ACC AGT TT 50-TGC TCC TCT GAG TTC CTC TGG
CDKN2a 9p21 50-CGC GCC GTG GAG CA 50-CCC AAC GCA CCG AAT AGT TAC
b-Actin 50-TGG TGA TGG AGG AGG TTT AGT AAG T 50-AAC CAA TAA AAC CTA CTC CTC CCT TAA
SOCS-1 16p13.3 50-GCG TCG AGT TCG TGG GTA TTT 50-CCG AAA CCA TCT TCA CGC TAA
SOCS-2 12q12 50-TCC CTT CCC CGC CAT T 50-TTG TTT TTG TCG CGG TGA TTT
RASSF1a 3p21 50-ATT GAG TTG CGG GAG TTG GT 50-ACA CGC TCC AAC CGA ATA CG
MGMT 10q26 50-GCG TTT CGA CGT TCG TAG GT 50-CAC TCT TCC GAA AAC GAA ACG
CDKN2a 9p21 50-TGG AGT TTT CGG TTG ATT GGT T 50-AAC AAC GCC CGC ACC TCC TT
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transcription of this gene in the tumors. Interestingly,
individuals with basal cell cancer showed methylation for
CDKN2A in 43% and RASSF1a in 86%. As epigenetic
mosaicism has potential implications for the pathogenesis of
several age-related diseases, the validity of our results in this
patient population was confirmed by the absence of similar
methylation events in an age-related control group. However,
older individuals with inflammatory diseases also showed
increased levels of methylation, which has recently been
reported (Holdenrieder et al., 2005).
MGMT, a DNA repair gene, serves as a key regulator of
genome integrity. Studies have shown that MGMT expression
protects mammalian cell lines from spontaneous G:C to A:T
transitions (Christmann et al., 2001). Lately, Hoon et al.
(2004) showed methylation of MGMT in 34% of metastatic
tumor specimens and also in the plasma of melanoma
patients. However, contradicting reports exist as to the
presence of MGMT methylation in melanoma. For instance,
Paz et al. (2003) or Furuta et al. (2004) analyzed the MGMT
methylation of the enhancer and the minimal promoter
region by methylation-specific PCR and found no methyla-
tion. Nakagawachi et al. (2003) recently pointed to the
importance of the position for MGMT silencing.
Our data on pyrosequencing for the SOCS2 promoter
serve as an example to identify the critical CpG sites whose
methylation results in decreased gene expression. Additional
detailed pyrosequencing studies are necessary to identify the
critical CpG island for all genes to be analyzed. These
positional methylation experiments will undoubtedly help to
resolve some of the controversies in semiquantitative studies
published up to now.
Circulating methylated DNA and detection of TSG
promoter methylation in serum may hold promise as a
surrogate marker of cancer to detect recurrence or progres-
sion. Detailed studies on larger numbers of patients are
needed to reveal their potential usefulness as a surrogate
marker.
MATERIALS AND METHODS
Patients and serum samples
A total of 100 peripheral blood specimens were collected. We
analyzed the sera from 41 patients (stage I¼ 18; stage II¼ 10; stage
III/IV¼ 13). For comparison, sera from 13 healthy controls without
nevi and 10 individuals with more than 15 nevi of 45 mm in size
and patients with other skin tumors (nine basal cell cancers, five
Kaposi’s sarcoma) as well as different cancers (five breast cancers,
five colon cancers) were used as controls. In addition, we examined
12 individuals suffering from chronic inflammatory diseases such as
psoriasis and eczema.
The experiments received institutional approval and patients
consented to the blood analysis. The protocol adhered to the
Declaration of Helsinki Principles.
Sample preparation
Genomic DNA was isolated from 1 ml serum using QIAmp
Ultrasense blood mini kit (Qiagen) according to the manufacturer’s
protocol, with an elution volume of 50ml. DNA samples were frozen
at 701C until further processing.
Analysis of DNA methylation
Chemical modification of unmethylated, but not of the methylated,
cytosines to thymidine within CpG islands using sodium bisulfite
treatment was performed using the CpGTM DNA modification kit
(Chemicon). The protocol was modified by using 3mg of serum
DNA. After bisulfite modification, the DNA was eluted in 75ml H2O.
Primers and probes were designed to specially amplify the bisulfite-
converted promoter of the genes of interest. Primers and probes of
the b-actin gene were located in an area lacking CpG nucleotides;
thus, the amplification of the reference gene by methylation-specific
PCR occurred independently of the CpG island methylation status,
whereas the amplification of the TSG was proportional to the degree
of cytosine methylation within the promoter. The methylation status
was defined as the ratio of the fluorescence emission intensity values
for each gene’s PCR product to those of the b-actin PCR products
obtained by the SYBR analysis (see below) (Widschwendter et al.,
2004; Lehmann et al., 2005). A threshold was defined individually
for every gene: the ratio (target gene:b-actin) was used as a relative
measure for the level of the methylated target gene DNA in a
particular sample. The PCR was performed in triplicates for each
primer/probe set. Analysis of methylation of the b-actin gene was run
in all samples for verification of modified DNA. A gene was deemed
as methylated if this value was 41.
Quantitative real-time PCR and isolation of total RNA
Total RNA from fresh tumors was isolated using Trizols according to
the manufacturer’s recommendation (Invitrogen Life Technology).
First-strand cDNA was synthesized in 20 ml reaction volume
containing 5 mM MgCl2, 1 mM dNTP mix, 1 PCR buffer (50 mM
KCl, 10 mM Tris-HCl, pH 8.3), 2.5 mM random hexamer, 1 U/ml RNA
guard, 2.5 U/ml MuLV reverse transcriptase, and 1mg of total RNA.
Samples were incubated for 10 minutes at 201C, and for 15 minutes
at 421C, followed by 5 minutes at 991C. The quality of the resulting
cDNA was checked by electrophoresis on a 3% (w/v) agarose gel.
The cDNA was diluted four times before using in PCR. Statistical
analysis was performed using the Student’s t-test.
Quantitative PCR based on the use of fluorogenic probes and
SYBRsgreen
The SYBRs green assay was used for all five genes listed above
(Giglio et al., 2003). Additionally, we confirmed the results for
three genes (SOCS1, RASSF1a, CDKN2a) using the TaqMans
technique. Transcript analysis of fresh tumors was performed by
real-time PCR using the SYBRs assay. Hybridization probes and
primers were designed using Primer Expresss version 2.0 (Perkin-
Elmer Applied Biosystems Inc., Warrington, UK), based on
sequences from the GenBank database (Table 4). Typically, PCR
was carried out in a 96-well plate containing 25ml volumes,
including universal master mix (1 ), 600 nM forward primers, and
600 nM reverse primer. A fluorescent dye, 6-carboxyl-X-rhodamin,
was included in the TaqMans buffer to serve as an internal
reference. Thermal cycling was initiated with a first denaturation
step for 10 minutes at 951C, followed by 50 cycles performed in two
steps: for 15 seconds at 951C and for 1 minutes at 601C. When using
the SYBRs assay, a dissociation curve was plotted after 50 PCR
cycles and analyzed to confirm the specificity of the PCR products
(Giglio et al., 2003). All samples were amplified simultaneously in
triplicates in a one-assay run. Variation coefficients for CT values for
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triplicate reactions were excellent (less than 2% for all gene
products).
Pyrosequencing
The Gene2Promoter software (www.genomatix.de; Genomatix Soft-
ware, Munich, Germany) allows the automated extraction of groups
of promoters from a list of accession numbers or gene IDs. We
extracted 2,500 bp upstream and 500 bp downstream around
the transcription start site of the promoter region. Subsequently,
CpG islands were identified within this core promoter region using
the EMBL EBI-CpG plot (www.ebi.ac.uk/emboss/cpgplot/index.
html).
For primer design, the DNA sequences were converted in silico
to the methylated form of CpG as follows: find CG, convert to YG,
and subsequently find C, convert to T, with Y equaling either C/T or
G/A. Using this converted sequence, methylation-specific primers
for pyrosequencing of SOCS2 CpGs were designed using the Biotage
Assay Design soft ware (Biotage, Uppsala, Sweden).
F-primer, Biotin-TTAAAGAGGGTAAGTGTT
TTGTGT
R-primer, TAGATTTTAAGGTTGGGAGTTGG
reverse complementary
Sequencing Primer, AATAAAGTTTTTTGTTAGTT
reverse complementary,
AACTAACAAAAAACTTTATT.
PCR conditions for pyrosequencing
Bisulfite-treated DNA (50 ng) from serum was used in the PCR
reaction with 10 mM forward and reverse primers, respectively. PCR
conditions for SOCS2 were 1 951C for 15 minutes (951C 40 s; 551C
40 seconds; 721C 40 seconds), 50 cycles, 1 721C 10 min.
For statistical analysis, the coefficient of variation was calculated
for SOCS2 methylation of healthy individuals versus patients with
nevi, melanoma, and melanoma metastases, respectively. A
coefficient of variation greater than the threshold of 0.2 was
considered significant.
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